DDIT3 and diffuse large B-cell lymphoma: With a median follow-up of 27.1 months, ORR, CR rate, and PFS did differ between the CHOP+/−R and CEpOP+/−R groups after adjustment for histology subtype (DLBCL vs. FLG3) and rituximab use (Table 2, Figure 2).